Evaluation of Acute Glial Fibrillary Acidic Protein and Ubiquitin C-Terminal Hydrolase-L1 Plasma Levels in Traumatic Brain Injury Patients with and without Intracranial Lesions

• Published in: Neurotrauma reports Vol. 2; no. 1; pp. 617 - 625
• Main Authors: Biberthaler, Peter, Musaelyan, Ksenia, Krieg, Sandro, Meyer, Bernhard, Stimmer, Herbert, Zapf, Julian, von Matthey, Francesca, Chandran, Raj, Marino, Jaime A, Beligere, Gangamani, Hoffmann, Markus, Zhang, Hongwei, Datwyler, Saul A, McQuiston, Beth
• Format: Journal Article
• Language: English
• Published: United States Mary Ann Liebert, Inc., publishers 01-12-2021; Mary Ann Liebert
• Subjects: blood biomarkers; glial fibrillary acidic protein; Original; Original Article; point-of-care platform; S100 calcium-binding protein B, traumatic brain injury; ubiquitin C-terminal hydrolase L1; point-of-care platform; blood biomarkers; S100 calcium-binding protein B, traumatic brain injury; glial fibrillary acidic protein; ubiquitin C-terminal hydrolase L1
• ISSN: 2689-288X; 2689-288X
• DOI: 10.1089/neur.2021.0048

This pilot study aimed to evaluate the association of plasma ubiquitin C-terminal hydrolase-L1 (UCH-L1), glial fibrillary acidic protein (GFAP), and S100 calcium-binding protein B (S100B) with intracranial abnormalities visible on a computed tomography (CT) scan (CT positive) and injury severity in acute traumatic brain injury (TBI). For these purposes, a cohort of 109 adult TBI patients was recruited within 6 h from the injury event. A hyperacute subcohort of 20 patients who had their blood collected within 2 h from injury was analyzed separately for early acute biomarker levels. Levels of GFAP and UCH-L1 were analyzed using the prototype Abbott i-STAT™ TBI Plasma Test (Abbott Laboratories, Abbot Park, IL), alongside S100B measurement (Elecsys; Roche Diagnostics, Penzberg, Germany). In the hyperacute subcohort, GFAP and UCH-L1, but not S100B, levels were significantly higher in the CT-positive group compared to CT-negative patients. AUC values for differentiation between CT-positive and CT-negative patients were 0.97 for GFAP, 0.87 for UCH-L1, and 0.60 for S100B. Severity discrimination, defined by Glasgow Coma Scale (GCS) score, was then analyzed in the total patient cohort. Levels of all three biomarkers were significantly different between mild (GCS, 13–15) and moderate/severe (GCS, 3–12) injury groups. UCH-L1 showed the highest area under the curve value for severity discrimination (0.94), followed by GFAP (0.91) and S100B (0.83). These results support the clinical utility of GFAP and UCH-L1 as TBI biomarkers able to rule out CT-positive injury in acute TBI. Moreover, excellent differentiation of GFAP and UCH-L1 between mild and moderate/severe TBI groups affirms their close association with the underlying pathology.